Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

155
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
155

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Plasma and Tissue Lipid Profiling Demonstrates a Distinctive Metabolic Profile in MAFLD-Associated Non-Cirrhotic Hepatocellular Carcinoma.

International journal of molecular sciences·2026
Same author

Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.

Journal of gastroenterology·2026
Same author

A decade of progress towards the elimination of hepatitis C: From the National Strategic Plan to Artificial Intelligence.

Gastroenterologia y hepatologia·2026
Same author

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.

Gut·2026
Same author

Liver Aging Index: A Noninvasive Score for Liver Biological Aging and Liver-Related Outcomes in Multicohorts.

Aging cell·2026
Same author

Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice.

Nature reviews. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Aug 4, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.2K

Predicting liver-related events in NAFLD: A predictive model.

Luis Calzadilla-Bertot1, Gary P Jeffrey1,2, Zhengyi Wang1

  • 1Medical School, University of Western Australia, Nedlands, Western Australia, Australia.

Hepatology (Baltimore, Md.)
|March 30, 2023
PubMed
Summary

A new NAFLD Outcomes Score (NOS) accurately predicts liver-related events in non-alcoholic fatty liver disease patients. This score outperforms existing fibrosis models for predicting outcomes.

More Related Videos

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.1K
Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

1.9K

Related Experiment Videos

Last Updated: Aug 4, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.2K
Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.1K
Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
08:20

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

1.9K

Area of Science:

  • Hepatology
  • Medical Informatics
  • Predictive Modeling

Background:

  • Non-alcoholic fatty liver disease (NAFLD) management requires accurate prediction of patient outcomes.
  • Fibrosis staging is a common surrogate for predicting outcomes in NAFLD.
  • There is a need for models that directly predict liver-related events (LREs).

Purpose of the Study:

  • To develop and validate a predictive model for liver-related events (LREs) in NAFLD patients.
  • To compare the accuracy of the new model against established fibrosis prediction models.
  • To identify key clinical predictors of LREs in NAFLD.

Main Methods:

  • Development and validation of a predictive model using competing risk regression on derivation and validation cohorts (n=584, n=477).
  • Inclusion of clinical variables such as age, type 2 diabetes, albumin, bilirubin, platelet count, and international normalized ratio.
  • Accuracy assessment using time-dependent Area Under the Curve (AUC) analysis and calibration metrics.

Main Results:

  • The NAFLD Outcomes Score (NOS) was developed, incorporating readily available clinical measures.
  • The NOS demonstrated excellent calibration and performance in both derivation and validation cohorts.
  • NOS showed superior accuracy (time-dependent AUC) compared to FIB-4 and NAFLD Fibrosis Score for predicting LREs at 5 and 10 years.

Conclusions:

  • The NAFLD Outcomes Score (NOS) is a validated tool for predicting liver-related events in NAFLD.
  • NOS offers greater predictive accuracy for patient outcomes than current fibrosis staging models.
  • The model utilizes easily accessible clinical data, facilitating clinical application.